HRP20251144T1 - Anti-fgfr2 protutijela u kombinaciji s kemoterapeutskim sredstvima u liječenju raka - Google Patents

Anti-fgfr2 protutijela u kombinaciji s kemoterapeutskim sredstvima u liječenju raka

Info

Publication number
HRP20251144T1
HRP20251144T1 HRP20251144TT HRP20251144T HRP20251144T1 HR P20251144 T1 HRP20251144 T1 HR P20251144T1 HR P20251144T T HRP20251144T T HR P20251144TT HR P20251144 T HRP20251144 T HR P20251144T HR P20251144 T1 HRP20251144 T1 HR P20251144T1
Authority
HR
Croatia
Prior art keywords
fgfr2
antibody
days
iiib
amino acid
Prior art date
Application number
HRP20251144TT
Other languages
English (en)
Croatian (hr)
Inventor
Helen L. COLLINS
James Hnatyszyn
Hong Xiang
Xiang Zhang
Original Assignee
Five Prime Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics, Inc. filed Critical Five Prime Therapeutics, Inc.
Publication of HRP20251144T1 publication Critical patent/HRP20251144T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20251144TT 2017-05-16 2018-05-15 Anti-fgfr2 protutijela u kombinaciji s kemoterapeutskim sredstvima u liječenju raka HRP20251144T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762507053P 2017-05-16 2017-05-16
US201762581992P 2017-11-06 2017-11-06
EP18730518.0A EP3624837B1 (en) 2017-05-16 2018-05-15 Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
PCT/US2018/032757 WO2018213304A1 (en) 2017-05-16 2018-05-15 Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment

Publications (1)

Publication Number Publication Date
HRP20251144T1 true HRP20251144T1 (hr) 2025-12-05

Family

ID=62567776

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20251144TT HRP20251144T1 (hr) 2017-05-16 2018-05-15 Anti-fgfr2 protutijela u kombinaciji s kemoterapeutskim sredstvima u liječenju raka

Country Status (22)

Country Link
US (2) US11091555B2 (cg-RX-API-DMAC7.html)
EP (2) EP4650004A2 (cg-RX-API-DMAC7.html)
JP (3) JP7299842B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250010107A (cg-RX-API-DMAC7.html)
CN (2) CN118416216A (cg-RX-API-DMAC7.html)
AU (2) AU2018269984B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019023898A2 (cg-RX-API-DMAC7.html)
CA (1) CA3062177A1 (cg-RX-API-DMAC7.html)
DK (1) DK3624837T3 (cg-RX-API-DMAC7.html)
ES (1) ES3041987T3 (cg-RX-API-DMAC7.html)
FI (1) FI3624837T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251144T1 (cg-RX-API-DMAC7.html)
IL (1) IL270454B2 (cg-RX-API-DMAC7.html)
LT (1) LT3624837T (cg-RX-API-DMAC7.html)
MX (1) MX2024000614A (cg-RX-API-DMAC7.html)
PL (1) PL3624837T3 (cg-RX-API-DMAC7.html)
PT (1) PT3624837T (cg-RX-API-DMAC7.html)
RS (1) RS67296B1 (cg-RX-API-DMAC7.html)
SG (1) SG10202112636SA (cg-RX-API-DMAC7.html)
SI (1) SI3624837T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500362T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018213304A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021552742A1 (en) 2013-08-01 2022-05-23 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
CN116327924A (zh) * 2015-11-23 2023-06-27 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
PT3624837T (pt) 2017-05-16 2025-10-01 Five Prime Therapeutics Inc Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro
CA3160812A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
CN111760026A (zh) * 2020-08-06 2020-10-13 汪炬 FGFR2b抑制分子在制备治疗PAF介导的疾病药物中的应用
EP4273166A4 (en) * 2020-12-29 2025-04-16 Shenzhen Forward Pharmaceuticals Co., Limited ANTI-FGFR2 ANTIBODIES AND USE THEREOF
TW202342527A (zh) * 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
CN117917435A (zh) * 2022-10-21 2024-04-23 北京天广实生物技术股份有限公司 结合fgfr2b的抗体及其用途
WO2024140834A1 (en) * 2022-12-28 2024-07-04 Suzhou Transcenta Therapeutics Co., Ltd. Anti-fgfr2b antibody and uses thereof
WO2025067442A1 (zh) * 2023-09-28 2025-04-03 南京维立志博生物科技股份有限公司 抗fgfr2抗体和包含其的多特异性结合分子
WO2025103358A1 (en) * 2023-11-14 2025-05-22 Suzhou Transcenta Therapeutics Co., Ltd. Anti-fgfr2b immunoconjugates and their use in the treatment of cancer
TW202527998A (zh) * 2023-12-18 2025-07-16 大陸商山東先聲生物製藥有限公司 抗FGFR2b抗體-藥物綴合物及其應用
CN120424212A (zh) * 2024-01-26 2025-08-05 上海安领科生物医药有限公司 抗FGFR2b抗体及抗体药物偶联物
CN117925825B (zh) * 2024-01-31 2024-09-13 中国医学科学院北京协和医院 包含ncoa7的标志物组合在诊断圆锥角膜中的应用
WO2025218662A1 (zh) * 2024-04-16 2025-10-23 杭州中美华东制药有限公司 抗成纤维细胞生长因子受体2b的抗体及其用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2133271T3 (es) 1989-07-06 1999-09-16 Univ California Receptores para factores de crecimiento de fibroblastos.
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU3494397A (en) 1996-06-18 1998-01-07 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fibroblast growth factor receptor activating gene i and related compositions and methods
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2278003B2 (en) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CN1308347C (zh) 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EA013563B1 (ru) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
AU2002314495A1 (en) 2001-06-20 2003-01-02 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
HUP0700103A3 (en) 2001-08-03 2012-09-28 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
JP2005532253A (ja) 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド 糖タンパク質組成物
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN100531796C (zh) 2002-01-31 2009-08-26 马普科技促进协会 Fgfr激动剂
CA2492671C (en) 2002-03-22 2012-04-17 Aprogen, Inc. Humanized antibody and process for preparing same
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PRODUCING ANTIBODY COMPOSITION
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
KR100493460B1 (ko) 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
US20070274981A1 (en) 2003-10-16 2007-11-29 Imclone Systems Incorporation Fibroblast Growth Factor Receptor-1 Inhibitors and Methods of Treatment Thereof
NZ547279A (en) 2003-10-22 2008-04-30 Keck Graduate Inst Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
EP1697420A2 (en) 2003-12-19 2006-09-06 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
WO2005115363A2 (en) 2004-05-25 2005-12-08 Yale University Method for treating skeletal disorders resulting from fgfr malfunction
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
EP2041575A2 (en) 2006-03-31 2009-04-01 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
WO2007134210A2 (en) 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
WO2007146847A2 (en) 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
HRP20160082T1 (hr) 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
US8394927B2 (en) 2006-11-03 2013-03-12 U3 Pharma Gmbh FGFR4 antibodies
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
TW200833711A (en) 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008090959A1 (ja) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. エフェクター活性が増強された遺伝子組換え抗体組成物
CA2680046A1 (en) 2007-03-23 2008-10-02 The Translational Genomics Research Institute Methods of diagnosing, classifying and treating endometrial cancer and precancer
CA2682382A1 (en) 2007-03-28 2008-10-09 Biogen Idec Inc. Non-fucosylated antibodies
US20110091473A1 (en) 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
WO2009151448A1 (en) 2008-06-10 2009-12-17 University Of Southern California Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
LT2842573T (lt) 2008-11-07 2017-12-11 Galaxy Biotech, Llc Monokloniniai antikūnai prieš fibroblastų augimo faktoriaus receptorių-2
WO2011025814A1 (en) 2009-08-25 2011-03-03 National Jewish Health Methods and compositions for treatment of lung injury
JP2013508292A (ja) 2009-10-14 2013-03-07 カロバイオス ファーマシューティカルズ インコーポレイティッド ＥｐｈＡ３に対する抗体
US20120328599A1 (en) 2010-01-14 2012-12-27 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
WO2011115937A1 (en) 2010-03-14 2011-09-22 The Translational Genomics Research Institute Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
AU2011253101A1 (en) 2010-05-11 2013-01-10 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN103201287B (zh) 2010-08-12 2016-04-13 艾托生物有限公司 成纤维细胞生长因子受体2的致癌异构体的抗体分子及其用途
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
WO2012162561A2 (en) * 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
JP2015505850A (ja) 2011-12-14 2015-02-26 シアトル ジェネティックス， インコーポレイテッド 新規な抗体薬物コンジュゲート（ａｄｃ）およびそれらの使用
US20150329621A1 (en) 2012-03-30 2015-11-19 The Regents Of The University Of California Anti-emp2 therapy reduces cancer stem cells
KR102115143B1 (ko) 2012-04-09 2020-05-28 다이이찌 산쿄 가부시키가이샤 항 ｆｇｆｒ２ 항체
US9254288B2 (en) 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US20150191791A1 (en) 2012-07-05 2015-07-09 Lsip, Llc Fgfr2 fusion gene
WO2014089193A1 (en) 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
US10980804B2 (en) 2013-01-18 2021-04-20 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9415118B2 (en) 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
AU2014259956A1 (en) 2013-05-01 2015-11-12 Five Prime Therapeutics, Inc. Methods of treating cancer
CN105658810B (zh) 2013-06-13 2020-08-21 南澳大学 用于检测前列腺癌的方法
PH12021552742A1 (en) 2013-08-01 2022-05-23 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20170175197A1 (en) 2014-01-29 2017-06-22 Caris Mpi, Inc. Molecular profiling of immune modulators
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN116327924A (zh) 2015-11-23 2023-06-27 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
PT3624837T (pt) 2017-05-16 2025-10-01 Five Prime Therapeutics Inc Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro

Also Published As

Publication number Publication date
AU2025210842A1 (en) 2025-10-02
KR20250010107A (ko) 2025-01-20
SI3624837T1 (sl) 2025-11-28
KR102749931B1 (ko) 2025-01-03
JP7573062B2 (ja) 2024-10-24
LT3624837T (lt) 2025-10-10
KR20200006538A (ko) 2020-01-20
EP3624837B1 (en) 2025-07-30
US20200079856A1 (en) 2020-03-12
IL270454B2 (en) 2025-10-01
US12319738B2 (en) 2025-06-03
EP4650004A2 (en) 2025-11-19
JP2020520903A (ja) 2020-07-16
RU2019141070A (ru) 2021-06-16
JP7299842B2 (ja) 2023-06-28
EP3624837A1 (en) 2020-03-25
RS67296B1 (sr) 2025-11-28
CA3062177A1 (en) 2018-11-22
PT3624837T (pt) 2025-10-01
CN118416216A (zh) 2024-08-02
PL3624837T3 (pl) 2025-12-08
RU2019141070A3 (cg-RX-API-DMAC7.html) 2021-09-10
JP2023093527A (ja) 2023-07-04
IL270454B1 (en) 2025-06-01
MX2024000614A (es) 2024-02-02
US11091555B2 (en) 2021-08-17
AU2018269984B2 (en) 2025-05-01
ES3041987T3 (en) 2025-11-17
US20220041737A1 (en) 2022-02-10
DK3624837T3 (da) 2025-09-29
JP2025004195A (ja) 2025-01-14
BR112019023898A2 (pt) 2020-06-09
AU2018269984A1 (en) 2019-12-05
SG10202112636SA (en) 2021-12-30
CN110621336B (zh) 2024-05-14
IL270454A (cg-RX-API-DMAC7.html) 2019-12-31
SMT202500362T1 (it) 2025-11-10
CN110621336A (zh) 2019-12-27
WO2018213304A1 (en) 2018-11-22
FI3624837T3 (fi) 2025-09-30

Similar Documents

Publication Publication Date Title
HRP20251144T1 (hr) Anti-fgfr2 protutijela u kombinaciji s kemoterapeutskim sredstvima u liječenju raka
JP2025004195A5 (cg-RX-API-DMAC7.html)
JP2023093527A5 (cg-RX-API-DMAC7.html)
CN109071639B (zh) Pd1/ctla4结合剂
IL294800A (en) Methods for treatment of cancer with an anti-tigit antagonist antibody
RU2018110333A (ru) Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
IL291926B1 (en) FGFR2 inhibitors alone or in combination with immunostimulating agents in cancer treatment
FI3791896T3 (fi) Claudin-18.2:n vasta-aineita sisältävä yhdistelmähoito syövän hoitoon
JP2018508512A5 (cg-RX-API-DMAC7.html)
JP2017501167A5 (cg-RX-API-DMAC7.html)
JP2020508317A5 (cg-RX-API-DMAC7.html)
NZ760065A (en) Methods of treating cancers using pd-1 axis binding antagonists and taxanes
JP2018522851A5 (cg-RX-API-DMAC7.html)
CN108601831A (zh) 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途
JP2014522843A5 (cg-RX-API-DMAC7.html)
JP2015525798A5 (cg-RX-API-DMAC7.html)
RU2012131411A (ru) АНТИТЕЛА ПРОТИВ Bv8 И ИХ ПРИМЕНЕНИЕ
JPWO2021154761A5 (cg-RX-API-DMAC7.html)
US20120020989A1 (en) Methods of treating colorectal cancer
CN109806393B (zh) 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途
JPWO2022187539A5 (cg-RX-API-DMAC7.html)
JP2020521798A5 (cg-RX-API-DMAC7.html)
RU2013140471A (ru) Дозирование для лечения антителами против egfl7
IL307430A (en) Methods for treating cancer with subcutaneous administration of anti-pd1 antibodies
RU2023114068A (ru) Антитела к fgfr2 в комбинации с химиотерапевтическими средствами при лечении рака